For people who have severe congenital<unk>  C deficiency,<unk>  C replacement therapies are available, which is indicated and approved for use in the United States and Europe for the prevention of purpura fulminans.<unk>  C replacement is often in combination with anticoagulation therapy of injectable low molecular weight heparin or oral warfarin. Before initiating warfarin therapy, a few days of therapeutic heparin may be administered to prevent warfarin necrosis and other progressive or recurrent thrombotic complications. Complications of prevention The amount of fresh frozen plasma required to reverse disseminated intravascular coagulation associated with purpura fulminans may lead to complications of fluid overload and death, especially in neonates, such as transfusion-related acute lung injury. Exposure to multiple plasma donors over time increases the cumulative risk for transfusion-associated viral infection and allergic reaction to donor<unk> s found in fresh frozen plasma. Allergic reactions and alloantibody formation are also potential complications, as with any<unk>  replacement therapy. Concomitant warfarin therapy in subjects with congenital<unk>  C deficiency is associated with an increased risk of warfarin skin necrosis.
symptom of Protein S deficiency
symptom of Vitamin K deficiency
symptom of Haemophilia
medical cause of Protein S deficiency
symptom of HELLP syndrome
symptom of Disseminated intravascular coagulation
symptom of Atransferrinemia
symptom of Babesiosis